This is Bum-Joon Park, a professor in the Department of Molecular Biology at Pusan University and the CEO of the company, PRG Science and Technology. I majorly studied Cancer biology during my Ph.D. course and postdoctoral training. After being employed as an assistant professor at Pusan University, I focused on finding target sites for the therapeutic treatment of several diseases related to aging, cancer, neurodegeneration, etc. until now. Those research made me find some candidate drugs for HGPS, NF2, ALS, etc. This could make me establish a biotech company for therapeutics, PRG S&T in Busan South Korea on September 2017 (www.prgst.com/eng). Especially, an asset (Progerinin) for the HGPS was initiated the phase 2 clinical trial in Jan 2025 at Boston Children’s Hospital (PI: Dr. Monika). And an asset (PRG-N-01) for NF2 was initiated syndrome on the phase 1/2 clinical trial in June 2024 at Seoul Hyundai Asan Hospital (PI: Dr. Beom Hee Lee). And an asset (PRG-A-05; Amisodin), which targets ALS disease, will be submitted for IND for the phase 1 clinical study to FDA in Apr 2025.